Kane Black

Kane Black has an extensive work experience in the medical technology and healthcare industry. Kane started his career in 2003 as Director of Adtec Corporation K.K in Tokyo Japan, then later became Asia - Representative Director at a Private Family Office - Healthcare Investments. Kane then served as a Director at Nova Satra Health from 2012 to 2014, and as a Director at Nova Satra Diagnostics Asia Limited from 2014 onwards. From 2016 to 2019, he held the positions of Director and Chief Executive at Nova Satra Dx, a molecular diagnostics company. In 2019, following a merger of Nova Satra Dx with INEX he became the Chief Executive Officer of INEX Innovate, a medical technology developer and laboratory operator. That same year, he also took on the role of Chief Executive at iGene Laboratory Pte Ltd. In 2020, he became the President Director of PT iGene Laboratory Indonesia, a joint venture between iGene Laboratory Pte Ltd and PT Itama Ranoraya Tbk. In 2021, he became a Member of the Singapore Institute of Directors and a Council Member of the NUS Yong Loo Lin School of Medicine. In 2024 he stood down as Chief Executive Officer of INEX Innovate, transitioning to the Board as Non-Executive Director and became Chief Executive Officer of London Stock Exchange listed investment company IKIGAI Ventures Limited (LSE:IKIV)

Kane Black started his education in 1994 when he participated in the AFS Intercultural Programs USA and went to Japan as an exchange student to study Japanese Studies. Kane continued his education in the same field at Fukuyama Myoodai High School in Hiroshima, Japan, for one year. In 1997, he completed their Senior School Certificate at The Southport School. Subsequently, from 1997 to 1999, he attended Griffith University, where he pursued a Bachelor of International Business (B.Int.Bus). Finally, from 1999 to 2003, he studied Cost Accounting at Bond University, earning a Bachelor of Business Administration (BBA) degree.